Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12630632 | 0.94 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL1859593 | 0.82 | HRH3 (0.78) | HRH3KCNH2SIGMAR1ALDH1A1ACHE | |
| SCHEMBL1857469 | 0.82 | HRH3 (0.78) | HRH3SIGMAR1 | |
| SCHEMBL1865018 | 0.78 | HRH3 (0.85) | HRH3ACHERAD52 | |
| SCHEMBL1860237 | 0.74 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1855965 | 0.74 | HRH3 (0.65) | HRH3 | |
| SCHEMBL3569242 | 0.74 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL3570492 | 0.74 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL1855803 | 0.73 | HRH3 (1.00) | HRH3KCNH2MAPK1SIGMAR1ALDH1A1 | |
| SCHEMBL28605278 | 0.72 | LTA4H (0.61) | HRH3SIGMAR1ALDH1A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | claimed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | claimed |
| EP-1761496-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-14 | — | — | EP | claimed |
| WO-2005097751-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | claimed |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | claimed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| EP-1761496-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005097751-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 1253/4885MAPK1 3907/4885 |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 692/4885MAPK1 2269/4885 |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 692/4885MAPK1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.